Radiation Therapy for Recurrent or Residual Pituitary Macroadenoma Invading Extrasellar Structures
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the efficacy of radiation therapy (RT) for recurrent or residual pituitary macroadenoma(PMA) invading extrasellar regions. Materials and Methods: Patients from 2000 to 2020 who received RT with conventional fractionation for recurrent or residual PMA were included. The patients were divided according to the type of tumor [functioning (fx) or non-fx] and the aim of RT (salvage RT alone, immediate postoperative RT, delayed postoperative RT). Local and biochemical failure-free rates (FFR) were calculated using the Kaplan–Meier method. Results: With a median follow up of 82 months (IQR; 42–132 months), 36 patients treated with conventional RT (total 45–54 Gy in 1.8 or 2 Gy per fraction) for recurrent or residual PMA were analyzed. The 10-year local FFRs after RT for non-fx and fx tumor were 100% and 74.4%, respectively (p=0.047). In the immediate postoperative RT group, the 10-year local FFR was 100%, which was higher than the 90% FFR for salvage RT alone or 80% FFR for the delayed postoperative RT group (overall p=0.043, immediate vs. salvage; p=0.312, immediate vs. delayed; p=0.072). The local FFR was compared according to size of tumor with a cut-off value of 4 cm, andthere was no significant difference (10-year local FFR 100% vs. 84.7% for >4 cm vs. <4 cm, p=0.320). The extents of extrasellar region invasion were not predictive of local failure after RT. We found no grade ≥3 acute toxicities or newly developed visual impairments as a late toxicity of RT. Conclusion: Conventional RT is safe and effective for the local control of recurrent or residual PMA. Our data suggest that immediate postoperative RT can be beneficial in recurrent or residual PMA, although further studies to evaluate risk factors of treatment failure in terms of treatment and disease characteristics are required.
Abstract
Purpose: This study aimed to evaluate the efficacy of radiation therapy (RT) for recurrent or residual pituitary macroadenoma(PMA) invading extrasellar regions. Materials and Methods: Patients from 2000 to 2020 who received RT with conventional fractionation for recurrent or residual PMA were included. The patients were divided according to the type of tumor [functioning (fx) or non-fx] and the aim of RT (salvage RT alone, immediate postoperative RT, delayed postoperative RT). Local and biochemical failure-free rates (FFR) were calculated using the Kaplan–Meier method. Results: With a median follow up of 82 months (IQR; 42–132 months), 36 patients treated with conventional RT (total 45–54 Gy in 1.8 or 2 Gy per fraction) for recurrent or residual PMA were analyzed. The 10-year local FFRs after RT for non-fx and fx tumor were 100% and 74.4%, respectively (p=0.047). In the immediate postoperative RT group, the 10-year local FFR was 100%, which was higher than the 90% FFR for salvage RT alone or 80% FFR for the delayed postoperative RT group (overall p=0.043, immediate vs. salvage; p=0.312, immediate vs. delayed; p=0.072). The local FFR was compared according to size of tumor with a cut-off value of 4 cm, andthere was no significant difference (10-year local FFR 100% vs. 84.7% for >4 cm vs. <4 cm, p=0.320). The extents of extrasellar region invasion were not predictive of local failure after RT. We found no grade ≥3 acute toxicities or newly developed visual impairments as a late toxicity of RT. Conclusion: Conventional RT is safe and effective for the local control of recurrent or residual PMA. Our data suggest that immediate postoperative RT can be beneficial in recurrent or residual PMA, although further studies to evaluate risk factors of treatment failure in terms of treatment and disease characteristics are required.
참고문헌 (38)
- Surawicz TS, "Descriptive epidemiology of primary brain and CNS tumors : results from the Central Brain Tumor Registry of the United States, 1990-1994", Neuro Oncol, 1, pp.14~25 (1999)
- Esposito V, "Transsphenoidal adenomectomy for GH-, PRL-and ACTH-secreting pituitary tumours : outcome analysis in a series of 125 patients", Neurol Sci, 25, pp.251~256 (2004)
- Mortini P, "Results of transsphenoidal surgery in a large series of patients with pituitary adenoma", Neurosurgery, 56, pp.1222~1233 (2005)
- Santoro A, "Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy : longterm endocrinologic follow-up results", Surg Neurol, 68, pp.513~518 (2007)
- 임채홍, "Radiotherapy for pituitary adenomas: long-term outcome and complications", Radiation oncology journal, 29(3), pp.156~163 (2011), 대한방사선종양학회
- Scheick S, "Long-term outcome after fractionated radiotherapy for pituitary adenoma : the curse of the secretory tumor", Am J Clin Oncol, 39, pp.49~54 (2016)
- Brada M, "The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas", Clin Endocrinol(Oxf), 38, pp.571~578 (1993)
- Dekkers OM, "Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma", J Clin Endocrinol Metab, 91, pp.1796~1801 (2006)
- Brochier S, "Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery : a study of 142 patients", Eur J Endocrinol, 163, pp.193~200 (2010)
- Losa M, "Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence", J Neurosurg, 108, pp.525~532 (2008)
- O’Sullivan EP, "The natural history of surgically treated but radiotherapynaïve nonfunctioning pituitary adenomas", Clin Endocrinol(Oxf), 71, pp.709~714 (2009)
- Raverot G, "European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas", Eur J Endocrinol, 178, pp.G1~G24 (2018)[DOI]
- Sheehan J, "Congress of neurological surgeons systematic review and evidence-based guideline for the management of patients with residual or recurrent nonfunctioning pituitary adenomas", Neurosurgery, 79, pp.E539~E540 (2016)
- Strickland BA, "Silent corticotroph pituitary adenomas : clinical characteristics, long-term outcomes, and management of disease recurrence", J Neurosurg, 135, pp.1706~1713 (2021)
- Erridge SC, "Radiotherapy for pituitary adenomas : long-term efficacy and toxicity", Radiother Oncol, 93, pp.597~601 (2009)
- "Common terminology criteria for adverse events (CTCAE) version 5.0. 2017"[URL]
- Aghi MK, "Management of recurrent and refractory Cushing disease", Nat Clin Pract Endocrinol Metab, 4, pp.560~568 (2008)
- Minniti G, "Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas : long-term clinical outcomes and volumetric MRI assessment of tumor response", Eur J Endocrinol, 172, pp.433~441 (2015)
- Kong DS, "The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas : long-term results of 125 consecutive patients treated in a single institution", Cancer, 110, pp.854~860 (2007)
- Hayhurst C, "Current perspectives on recurrent pituitary adenoma:the role and timing of surgery vs adjuvant treatment", Clin Endocrinol (Oxf), 92, pp.89~97 (2020)
- Saeger W, "Clinical implications of the new WHO classification 2017 for pituitary tumors", Exp Clin Endocrinol Diabetes, 129, pp.146~156 (2021)
- Pomeraniec IJ, "Early versus late gamma knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas : a matched cohort study", J Neurosurg, 125, pp.202~212 (2016)
- Iglesias P, "Giant pituitary adenoma : histological types, clinical features and therapeutic approaches", Endocrine, 61, pp.407~421 (2018)
- Scheithauer BW, "Clinically silent corticotroph tumors of the pituitary gland", Neurosurgery, 47, pp.723~729 (2000)
- Webb KM, "Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study", Neurosurgery, 53, pp.1076~1084 (2003)
- Ben-Shlomo A, "Silent corticotroph adenomas", Pituitary, 21, pp.183~193 (2018)
- Bradley KJ, "Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently", Clin Endocrinol(Oxf), 58, pp.59~64 (2003)
- Nishioka H, "New WHO classification of pituitary adenomas(4th edition) : assessment of pituitary transcription factors and the prognostic histological factors", Brain Tumor Pathol, 35, pp.57~61 (2018)
- Losa M, "Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas", Endocrine, 56, pp.595~602 (2017)
- Minniti G, "Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas", Rep Pract Oncol Radiother, 21, pp.370~378 (2016)
- Li X, "Safety and efficacy of fractionated stereotactic radiotherapy and stereotactic radiosurgery for treatment of pituitary adenomas : a systematic review and meta-analysis", J Neurol Sci, 372, pp.110~116 (2017)
- Minniti G, "Management of nonfunctioning pituitary tumors : radiotherapy", Pituitary, 21, pp.154~161 (2018)
- Forster N, "Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery", J Neurooncol, 138, pp.335~340 (2018)
- Kjellberg RN, "Proton-beam therapy in acromegaly", N Engl J Med, 278, pp.689~695 (1968)
- Lesueur P, "Proton therapy for treatment of intracranial benign tumors in adults : a systematic review", Cancer Treat Rev, 72, pp.56~64 (2019)
- Ronson BB, "Fractionated proton beam irradiation of pituitary adenomas", Int J Radiat Oncol Biol Phys, 64, pp.425~434 (2006)
- Sud S, "Dosimetric comparison of proton versus photon radiosurgery for treatment of pituitary adenoma", Adv Radiat Oncol, 6, pp.100806~ (2021)
- Hamblin R, "Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma : a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance", Lancet Diabetes Endocrinol, 10, pp.581~588 (2022)